Guardant Health, Inc. presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer (CRC).
Click on the press release link below to read the full story.